{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Fani Maleki A"],"funding":["CIHR"],"pagination":["218"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7376735"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["17(1)"],"pubmed_abstract":["<h4>Background</h4>Muramyl dipeptide (MDP) is a component derived from minimal peptidoglycan motif from bacteria, and it is a ligand for the NOD2 receptor. Peripheral administration of MDP converts Ly6C<sup>high</sup> into Ly6C<sup>low</sup> monocytes. Previously, we have shown that Ly6C<sup>low</sup> monocytes play crucial roles in the pathology of a mouse model of Alzheimer's disease (AD). However, medications with mild immunomodulatory effects that solely target specific monocyte subsets, without triggering microglial activation, are rare.<h4>Methods</h4>Three months old APP<sub>swe</sub>/PS1 transgenic male mice and age-matched C57BL/6 J mice were used for high frequency (2 times/week) over 6 months and low frequency (once a week) over 3 months of intraperitoneally MDP (10 mg/kg) admin"],"journal":["Journal of neuroinflammation"],"pubmed_title":["Muramyl dipeptide-mediated immunomodulation on monocyte subsets exerts therapeutic effects in a mouse model of Alzheimer's disease."],"pmcid":["PMC7376735"],"funding_grant_id":["331652"],"pubmed_authors":["Laflamme N","Plante MM","Gosselin J","Rivest S","Cisbani G","Prefontaine P","Fani Maleki A"],"additional_accession":[]},"is_claimable":false,"name":"Muramyl dipeptide-mediated immunomodulation on monocyte subsets exerts therapeutic effects in a mouse model of Alzheimer's disease.","description":"<h4>Background</h4>Muramyl dipeptide (MDP) is a component derived from minimal peptidoglycan motif from bacteria, and it is a ligand for the NOD2 receptor. Peripheral administration of MDP converts Ly6C<sup>high</sup> into Ly6C<sup>low</sup> monocytes. Previously, we have shown that Ly6C<sup>low</sup> monocytes play crucial roles in the pathology of a mouse model of Alzheimer's disease (AD). However, medications with mild immunomodulatory effects that solely target specific monocyte subsets, without triggering microglial activation, are rare.<h4>Methods</h4>Three months old APP<sub>swe</sub>/PS1 transgenic male mice and age-matched C57BL/6 J mice were used for high frequency (2 times/week) over 6 months and low frequency (once a week) over 3 months of intraperitoneally MDP (10 mg/kg) admin","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jul","modification":"2025-04-04T22:32:33.722Z","creation":"2025-04-04T22:32:33.722Z"},"accession":"S-EPMC7376735","cross_references":{"pubmed":["32698829"],"doi":["10.1186/s12974-020-01893-3"]}}